You are here

  • Home
  • Archive
  • Volume 94, Issue 5
  • Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia

Article info

Article menu
Download PDFPDF
Technology and guidelines
Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia

Authors

  1. J Armitage, Clinical Trial Service Unit, Richard Doll Building, Old Road Campus, University of Oxford, Oxford OX3 7LF, UK; jane.armitage{at}ctsu.ox.ac.uk
View Full Text

Citation

Armitage J
Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia
Heart 2008;94:643-645.

Publication history

  • Accepted January 15, 2008
  • First published April 14, 2008.
Online issue publication 
March 15, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

2008 BMJ Publishing Group and British Cardiovascular Society